Dimethyl Sulfoxide
Apexbio Technology LLC Micafungin sodium 208538-73-2 10mM (in 1mL DMSO)
Micafungin sodium is an antifungal agent that acts by inhibiting the synthesis of 1 3- -D-glucan an essential polymer for fungal cell wall integrity particularly in Candida albicans In addition to antifungal activities micafungin has been studied for its capacity to suppress biofilm formation by Pseudomonas aeruginosa via downregulation of genes encoding structural biofilm elements such as algC and pelC and the 1 3- -D-glucan-encoding gene ndvB Micafungin has demonstrated synergy with other antifungal compounds in animal models in murine models of systemic Aspergillus fumigatus infection micafungin administration resulted in increased survival rates Micafungin is utilized in biomedical research to investigate antifungal mechanisms combination therapies and inhibition of pathogen biofilms Reported inhibitory activity (IC50) for fungal glucan synthase typically falls within the nanomolar range
Sigma Aldrich Fine Chemicals Biosciences Dimethyl sulfoxide BioUltra, for molecular biology | 67-68-5 | MFCD00002089 | 100ml
Dimethyl sulfoxide BioUltra, for molecular biology | Purity: 99.5% | Mol Wt: 78.13 | 67-68-5 | MFCD00002089 | 100ml
Apexbio Technology LLC G007-LK 1380672-07-0 10mM (in 1mL DMSO)
G007-LK (CAS 1380672-07-0) is a small molecule inhibitor that selectively targets tankyrase 1 and 2 (TNKS1/2) enzymes within the poly(ADP-ribose) polymerase family that modulate protein complexes through ADP-ribosylation G007-LK inhibits TNKS1 and TNKS2 with IC50 values of 46 nM and 25 nM respectively reducing their auto-poly(ADP-ribosylation) activity Treatment with G007-LK decreases -catenin levels in APC-mutated colorectal cancer cells by promoting formation of -catenin degradation complexes In xenograft mouse models using COLO-320DM cells G007-LK administration suppresses tumor growth dose-dependently indicating its utility in oncology research focusing on the Wnt/ -catenin pathway
Apexbio Technology LLC PD 173074 219580-11-7 10mM (in 1mL DMSO)
PD 173074 (CAS 219580-11-7) is a selective inhibitor targeting fibroblast growth factor receptors (FGFR) exerting its effects by suppressing FGFR tyrosine kinase phosphorylation It has demonstrated dose-dependent inhibitory activity against small cell lung cancer (SCLC) cell lines including H-510 and H-69 by reducing their proliferation colony formation and FGF-2 induced chemotherapy resistance in vitro In murine xenograft models of SCLC PD 173074 reduced tumor progression and significantly prolonged animal survival achieving durable complete responses in some cases PD 173074 represents an important tool compound for investigating the oncogenic role of FGFR signaling in cancer research
Apexbio Technology LLC MRT67307 HCl 2095432-39-4 10mM (in 1mL DMSO)
MRT67307 HCl (CAS 2095432-39-4) is a small-molecule inhibitor targeting several kinases including TBK1 IKK MARK1-4 NUAK1 ULK1/2 and salt-inducible kinases (SIK1-3) It inhibits TBK1 and IKK to block phosphorylation of IRF3 reducing interferon- synthesis without affecting NF- B activation Additionally MRT67307-mediated SIK inhibition promotes regulatory macrophage differentiation leading to elevated anti-inflammatory cytokines (e g IL-10 IL-1ra) and decreased pro-inflammatory cytokines (IL-6 IL-12 TNF) It is utilized to investigate innate immunity macrophage polarization autophagy and inflammation pathways
Apexbio Technology LLC Salirasib 162520-00-5 10mM (in 1mL DMSO)
Salirasib (CAS 162520-00-5) chemically known as S-trans trans-farnesylthiosalicylic acid (FTS) is a synthetic inhibitor targeting Ras proteins Structurally mimicking the carboxy-terminal farnesylated cysteine found in Ras Salirasib disrupts Ras localization at the cellular membrane thereby reducing activity of H-ras K-ras and N-ras isoforms Research indicates that Salirasib reduces Ras protein levels by approximately 50% at concentrations of 25 50 M in Panc-1 pancreatic cancer cells In xenograft models it exhibits tumor growth inhibition alone and synergistically with gemcitabine Clinical phase I studies support its continued investigation in solid-tumor therapy recommending a dose of 600 mg/day
Apexbio Technology LLC INK 128 (MLN0128) 1224844-38-5 10mM (in 1mL DMSO)
INK 128 (MLN0128 CAS 1224844-38-5) is a selective inhibitor of the mammalian target of rapamycin (mTOR) a conserved serine/threonine kinase integral to the PI3K/AKT/mTOR signaling pathway This compound inhibits both mTOR complexes (mTORC1 and mTORC2) demonstrating an IC50 of approximately 1 nM In preclinical studies utilizing human pancreatic and HER2-positive breast cancer cell lines INK 128 significantly reduced cellular proliferation and viability via concentration- and time-dependent suppression of mTOR activity Moreover it exhibited notable tumor suppression in breast cancer xenograft models enhancing efficacy when combined with agents such as sorafenib sunitinib paclitaxel or lapatinib highlighting its potential value for oncology research and therapeutic development
Apexbio Technology LLC Rosiglitazone(Synonyms: Avandia, BRL-49653, Rosiglitazone Maleate, Rosiglitazone Base, BRL49653C, RGZ, Rosiglizole), 10mM (in 1mL DMSO), CAS: 122320-73-4.
Rosiglitazone (CAS 122320-73-4) is a synthetic thiazolidinedione (TZD) that functions as an agonist of peroxisome proliferator-activated receptor gamma (PPAR ) a nuclear receptor highly expressed in adipose tissues Upon ligand binding PPAR forms heterodimers with retinoid X receptors promoting transcriptional activation of genes regulating adipogenesis glucose uptake lipid metabolism and insulin sensitivity Through modulating fatty acid storage in adipose tissue and secretion of adipokines rosiglitazone significantly enhances insulin sensitivity making it extensively utilized in metabolic and diabetes research particularly type II diabetes studies
Apexbio Technology LLC Foretinib (GSK1363089) 849217-64-7 10mM (in 1mL DMSO)
Foretinib (GSK1363089 CAS 849217-64-7) is a small molecule inhibitor targeting receptor tyrosine kinases involved in angiogenesis and tumor progression notably receptors for vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) Foretinib inhibits tyrosine kinase activity of Met Ron KDR Flt-1 Flt-4 KIT Flt-3 Tie-2 and PDGFR / exhibiting IC50 values ranging from 0 4 to 9 6 nmol/L In cell-based assays foretinib reduces MET phosphorylation in mouse B16F10 melanoma and human PC-3 prostate cells (IC50 21 23 nmol/L) inhibits HGF-induced cell migration invasion and suppresses proliferation in B16F10 A549 and HT29 tumor cell lines Foretinib is utilized in preclinical cancer research targeting angiogenesis invasion and metastasis pathways
Apexbio Technology LLC PD0325901 391210-10-9 10mM (in 1mL DMSO)
PD0325901 (CAS 391210-10-9) is a small-molecule inhibitor selectively targeting mitogen-activated protein kinase kinase (MEK) an integral kinase within the RAS/RAF/MEK/ERK signaling cascade This pathway commonly exhibits elevated activity in various human cancers and contributes to cell proliferation survival and differentiation Treatment with PD0325901 reduces phosphorylated ERK (P-ERK) levels in vitro indicative of MEK inhibition In mouse tumor models administration of PD0325901 has demonstrated suppression of tumor growth underscoring its value as a research tool for elucidating MEK-mediated signaling and evaluating therapeutic potential in oncology
Apexbio Technology LLC ML-323(Synonyms: ML323, ML 323, USP1 inhibitor ML323, ML-323 USP1-UAF1 inhibitor, USP1/UAF1 inhibitor ML323), 10mM (in 1mL DMSO), CAS: 1572414-83-5.
ML-323 (CAS 1572414-83-5) is a small molecule inhibitor selectively targeting the USP1-UAF1 deubiquitinase complex with a reported IC50 of 76 nM USP1-UAF1 participates in DNA damage response pathways by regulating ubiquitination status of proteins such as PCNA and FANCD2 In cellular assays ML-323 inhibits USP1 UAF1-mediated deubiquitination enhancing cisplatin-induced cytotoxicity in human NSCLC (H596) and osteosarcoma (U2OS) cells The molecule shows minimal cytotoxicity alone and exhibits high selectivity over other human DUBs and protease families providing a valuable research tool for DNA repair and cancer biology studies
Apexbio Technology LLC Bindarit 130641-38-2 10mM (in 1mL DMSO)
Bindarit (CAS 130641-38-2) also known as AF-2838 is a synthetic small-molecule inhibitor targeting the CC chemokines MCP-1 (CCL2) MCP-2 (CCL8) and MCP-3 (CCL7) By suppressing the transcription and production of MCP proteins Bindarit reduces monocyte chemoattraction and inflammation In vitro data indicate that Bindarit inhibits LPS-induced MCP-1 synthesis in monocytes with an IC50 around 172 M and selectively decreases MCP expression without impacting unrelated cytokines such as IL-6 or IL-8 Animal studies demonstrate its potential to reduce inflammatory cell infiltration vascular smooth muscle cell proliferation and neointimal hyperplasia in rodent injury models highlighting its value for inflammation and cardiovascular disease research
Apexbio Technology LLC Vorapaxar 618385-01-6 10mM (in 1mL DMSO)
Vorapaxar (CAS 618385-01-6) is a selective inhibitor of protease-activated receptor 1 (PAR1) a G-protein coupled receptor activated by thrombin-mediated cleavage on platelet surfaces leading to platelet activation Derived from the natural product himbacine vorapaxar directly binds PAR1 inhibiting platelet aggregation induced by thrombin receptor-activating peptides (IC 25 nM) and thrombin itself (IC 47 nM) In phase III clinical trials in patients daily oral administration reduced the incidence of cardiovascular death or ischemic events highlighting its relevance as an antithrombotic research agent